Skip to main content
. 2022 Aug 5;17(8):e0268712. doi: 10.1371/journal.pone.0268712

Fig 2. Impact of SARS‐CoV‐2 infection on T, B and NK cell numbers in severe and moderate patients (* P< 0.05, ** P< 0.01).

Fig 2

Immunological markers were analyzed in 32 severe cases compared with 63 moderate cases. CD3+, CD4+ cells and FcγRIII (CD16) had a significant difference between the two groups. Due to the poorer prognosis with an increase in neutrophils that have FcγRIIIB and insignificant changes in NK cell count, the increase in CD16 is due to the increase in peripheral blood monocytes in patients with COVID-19.